Cemiplimab for Secondary Angiosarcomas
Condition(s):Secondary Angiosarcoma; Locally Advanced Sarcoma; MetastasisLast Updated:February 3, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Secondary Angiosarcoma; Locally Advanced Sarcoma; MetastasisLast Updated:February 3, 2022Recruiting
Condition(s):Merkel Cell Carcinoma; Cutaneous Squamous Cell CarcinomaLast Updated:February 22, 2024Recruiting
Condition(s):Cutaneous Squamous Cell Carcinoma; Squamous Cell Carcinoma; Advanced Squamous Cell CarcinomaLast Updated:August 9, 2023Withdrawn
Condition(s):Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and NeckLast Updated:November 4, 2022Terminated
Condition(s):Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer; Oropharynx Squamous Cell CarcinomaLast Updated:February 20, 2024Recruiting
Condition(s):Head and Neck Squamous Cell Carcinoma; HNSCC; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Oral Cavity; Squamous Cell Carcinoma of HypopharynxLast Updated:August 4, 2022Withdrawn
Condition(s):Colon CancerLast Updated:January 31, 2024Not yet recruiting
Condition(s):Non-small Cell Lung Cancer (NSCLC)Last Updated:February 22, 2024Recruiting
Condition(s):Metastatic Uveal MelanomaLast Updated:November 7, 2023Recruiting
Condition(s):Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell CarcinomaLast Updated:February 3, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.